Use of disease risk scores in pharmacoepidemiologic studies

被引:106
|
作者
Arbogast, Patrick G. [1 ]
Ray, Wayne A. [2 ,3 ]
机构
[1] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA
[3] Nashville Vet Adm, Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN 37232 USA
基金
美国医疗保健研究与质量局;
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROPENSITY SCORE; STRATIFICATION; DEATH;
D O I
10.1177/0962280208092347
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Automated databases are increasingly used in pharmacoepidemiologic studies. These databases include records of prescribed medications and encounters with medical care providers from which one can construct very detailed Surrogate measures for both drug exposure and covariates that are potential confounders. Often it is possible to track day-by-day changes in these variables. However, while this information is often critical for study success, its Volume can pose challenges for statistical analysis. One common approach is the use of propensity scores. An alternative approach is to construct a disease risk score. This is analogous to the propensity score in that it calculates a summary measure from the covariates. However, the disease risk score estimates the probability or rate of disease Occurrence conditional oil being unexposed. The association between exposure and disease is then estimated adjusting for the disease risk score in place of the individual covariates. This review describes the use of disease risk scores in phamacoepidemiologic studies, and includes a brief discussion of their history, a more detailed description of their construction and use, a summary of simulation Studies comparing their performance vis-a-vis traditional models, a comparison of their utility with that of propensity scores, and some further topics for future research.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 50 条
  • [1] The use of propensity scores in pharmacoepidemiologic research
    Perkins, SM
    Tu, WZ
    Underhill, MG
    Zhou, XH
    Murray, MD
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2000, 9 (02) : 93 - 101
  • [2] PHARMACOEPIDEMIOLOGIC STUDIES ON PSYCHIATRIC DRUGS USE IN SERBIA
    Divac, N.
    Prostran, M.
    Todorovic, Z.
    Gasic, M. Jasovic
    Tosevski, D. Lecic
    Stojanovic, R.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [3] The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies
    Zafari, Zafar
    Park, Jeong-eun
    Shah, Chintal H.
    Dosreis, Susan
    Gorman, Emily F.
    Hua, Wei
    Ma, Yong
    Tian, Fang
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2024, 193 (03) : 426 - 453
  • [4] A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and Adolescents
    Patten, Scott B.
    Waheed, Waqar
    Bresee, Lauren
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2012, 57 (12): : 717 - 721
  • [5] The state of use and utility of negative controls in Pharmacoepidemiologic studies
    Park, Jeong-eun
    Zafari, Zafar
    Shah, Chintal H.
    DosReis, Susan
    Gorman, Emily F.
    Hua, Wei
    Ma, Yong
    Tian, Fang
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 203 - 204
  • [6] Oral fluoroquinolone use and risk of peripheral neuropathy A pharmacoepidemiologic study
    Etminan, Mahyar
    Brophy, James M.
    Samii, Ali
    NEUROLOGY, 2014, 83 (14) : 1261 - 1263
  • [7] Performance of disease risk scores in case-control studies
    Arbogast, Patrick G.
    Kaltenbach, Lisa
    Ray, Wayne A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S106 - S107
  • [8] Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study
    Cheng, Jasmine Z.
    Sodhi, Mohit
    Etminan, Mahyar
    Carleton, Bruce C.
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (04) : 684 - 686
  • [9] Infant and toddler disease score for risk of hospitalization based on data from administrative claims is useful for pharmacoepidemiologic studies
    Mikaeloff, Yann
    Moride, Yola
    Khoshnood, Babak
    Weill, Alain
    Breart, Gerard
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S116 - S117
  • [10] The use of genetic risk scores in pharmacogenetics studies-A simulation study
    Uddin, Md Jamal
    Nordentoft, Merete
    Ekstrom, Claus Thorn
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 385 - 386